EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Approach to the Patient - Transitions in Osteoporosis Therapy

Bente L Langdahl iD, Natasha A Laursen iD, Vivi Mäkinen iD, Torben Harsløf iD, Anne Sophie Sølling iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgaf614 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Bente L Langdahl und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Internal Medicine, Aarhus University Hospital, DK-8200 Aarhus N, Denmark. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteoporosis, Anabolic Agents, Drug Substitution. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 82 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Moving toward a goal-directed-treatment strategy in osteoporosis necessitates considering the opportunities and challenges associated with transitions in osteoporosis therapy. Some transitions are straightforward; transition from bone anabolic treatment to antiresorptives maintains or further improves the bone mineral density (BMD) increase and the antifracture effect obtained during treatment with a bone anabolic. Transitions from one antiresorptive to another are also, in most cases, safe and may lead to further increases in BMD if the transition is from an oral antiresorptive to a parentally administrated antiresorptive, such as zoledronate or denosumab. However, challenges arise when transitioning from antiresorptives to bone anabolic treatment, as the anabolic effect will be blunted compared to the effect seen in treatment-naïve patients, and transitions involving discontinuation of denosumab after more than 2 to 3 years of treatment. Sequential treatment of osteoporosis is needed for many patients to prevent fractures and obtain BMD levels associated with an acceptable fracture risk. While not all treatment transitions are optimal, the majority are safe, except for transitioning from denosumab to a bone anabolic agent or discontinuation of denosumab without appropriate follow-up treatment. These specific transitions should be avoided.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsOsteoporosisAnabolic AgentsDrug SubstitutionHumansBone DensityDenosumabOsteoporotic Fractures

Stichwörter der Autor:innen

antiresorptivesbone anabolic treatmentgoal-directed treatmentosteoporosissequential treatmenttreatment discontinuation

Substanzen

Bone Density Conservation AgentsDenosumabAnabolic Agents

Autor:innen und Institutionen

  • Department of Endocrinology and Internal Medicine, Aarhus University Hospital, DK-8200 Aarhus N, Denmark.
  • Department of Clinical Medicine, Aarhus University, DK-8200 Aarhus N, Denmarklinical Medicine, Denmark.

ORCID-Profile: Bente L Langdahl, Natasha A Laursen, Vivi Mäkinen, Torben Harsløf, Anne Sophie Sølling

Zitieren

APA

Langdahl, B. L., Laursen, N. A., Mäkinen, V., Harsløf, T., & Sølling, A. S. (2026). Approach to the Patient - Transitions in Osteoporosis Therapy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf614

Vancouver

Langdahl BL, Laursen NA, Mäkinen V, Harsløf T, Sølling AS. Approach to the Patient - Transitions in Osteoporosis Therapy. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf614

BibTeX
@article{Langdahl2026,
  author = {Langdahl, Bente L and Laursen, Natasha A and Mäkinen, Vivi and Harsløf, Torben and Sølling, Anne Sophie},
  title = {Approach to the Patient - Transitions in Osteoporosis Therapy},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgaf614}
}
Kostenlos starten →